AnalystBook Research · Company Intelligence

Oncotelic Therapeutics, Inc.

OTLC

Built from Oncotelic Therapeutics, Inc.'s own SEC filings · updates as new filings land · every figure links to its source

or browse all covered companies

← Research Library

The read at a glance

Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.

  • Distress risk · Altman Z-Score 3.51 — safe zoneOK

Latest filings

  • 8-K · Company announcement2026-06-29
  • 10-Q · Quarterly report2026-05-14
  • 8-K · Company announcement2026-05-05
  • 8-K · Company announcement2026-04-16
  • 10-K · Annual report2026-04-15
In the full recordFree for 14 days
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, every figure source-linked🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask anything about Oncotelic Therapeutics, Inc., every answer cited🔒
  • The Intelligence Brief — added when Oncotelic Therapeutics, Inc.'s brief passes our SEC-figure check🔒

Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.

See the full OTLC record — start free

14-day free trial, no credit card. For research purposes only; not investment advice.